Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,297 across all filing types
Latest filing 2025-01-31 Transaction in Own Shar…
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Bavarian Nordic A/S, dated January 31, 2025, titled 'afslutning af aktietilbagekøbsprogram' (completion of share buyback program). It details the final transactions and the total number of shares repurchased (760,275 shares for DKK 150 million). This activity—the repurchase or transaction in a company's own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). Although it is a regulatory announcement, the specific nature of the content (share repurchase completion) makes POS a more precise classification than the general RNS fallback. The document length (4805 chars) is substantial enough to be the primary announcement, not just a pointer to a report.
2025-01-31 Danish
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 100% confidence The document explicitly announces the 'Completion of Share Buy-Back Program' and details the number of shares repurchased and the total transaction value, concluding with the resulting number of treasury shares. This activity directly relates to the company buying back or selling its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). Although it is a short announcement, the core content is the transaction detail itself, not an announcement *about* a report, making POS a better fit than RPA or RNS.
2025-01-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a press release dated January 31, 2025, announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive recommendation for the marketing authorization of Bavarian Nordic's chikungunya vaccine (VIMKUNYA®). This is an announcement regarding a significant regulatory milestone (positive opinion/recommendation) for a product, which is a type of corporate news release. It is not a full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). Since it is a specific announcement of a regulatory event (EMA recommendation) that is not covered by other specific codes like DIV, DIRS, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category, as it is a formal company announcement disseminated to the public/regulators about a regulatory process outcome. Given the context of a major regulatory development, RNS is the most appropriate general regulatory announcement code.
2025-01-31 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding Bavarian Nordic's chikungunya vaccine. This is a specific, material event announcement concerning regulatory progress and future commercialization plans, rather than a full periodic financial report (like 10-K or IR) or a general regulatory filing (RNS). It is an announcement of a significant development that impacts the company's operations and outlook. Since it is not a full financial report, an earnings release, or a proxy statement, and it relates to a major business development (regulatory approval pathway), it fits best under the general category of a significant corporate announcement. Given the options, this type of announcement, which is not explicitly covered by other specific codes (like DIV, CAP, or MANG), is often classified as a general Regulatory Filing (RNS) if it's a mandatory disclosure, or sometimes an Earnings Release (ER) if it contains key performance indicators, but here it is purely regulatory/product news. However, since it is a specific announcement about regulatory progress, and not a general 'catch-all' filing, I must check if any other category fits better. It is not a Call Transcript (CT), Director's Dealing (DIRS), or a Dividend Notice (DIV). It is a material event disclosure. In many databases, specific regulatory milestones that aren't earnings or capital structure changes fall under a general disclosure category. Given the provided definitions, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category) is the most appropriate fit for a specific, non-financial, material regulatory update that doesn't match the other specific codes.
2025-01-31 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release from Bavarian Nordic dated January 31, 2025, announcing that the CHMP has adopted a positive opinion recommending marketing authorization for their Chikungunya vaccine (VIMKUNYA®). This is a significant corporate event announcement regarding regulatory progress for a product, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It details clinical trial results and regulatory steps (EMA, FDA, MHRA). This type of announcement, which is a specific corporate update that doesn't fit the other specialized categories (like M&A, Director's Dealing, or Capital Change), is best classified as a general Regulatory Filing or Announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standard regulatory news that isn't a core financial report or a specific insider/governance filing. However, since it is a major announcement about a product approval pathway, it is often categorized under general corporate news. Since there is no specific 'Product Approval Update' category, and it is not a financial report, RNS serves as the best fit among the provided codes for a major, non-financial regulatory milestone announcement.
2025-01-31 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is titled "Company Announcement" and details a significant corporate event: Bavarian Nordic receiving a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding its Chikungunya vaccine. This is a specific, material update concerning regulatory progress and future product launch timelines, rather than a full financial report (like 10-K or IR), a transcript (CT), or a general regulatory filing (RNS). It is a specific announcement about a key business development. Since there is no specific category for 'Regulatory Approval Update' or 'Product News', the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general announcement of material, non-financial news, or potentially 'Capital/Financing Update' (CAP) if the approval is directly tied to immediate financing plans, but RNS is the best fit for a general, material, non-financial regulatory milestone announcement that doesn't fit other specific categories like DIRS, DIV, or M&A.
2025-01-31 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.